Cargando…

Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma

BACKGROUND: This study aims to reveal the serum tumor marker (STM) levels in lung adenocarcinoma (LUAD) histological subtypes and evaluate their values in predicting the solid and micropapillary components (SMC). METHODS: We retrospectively analyzed 3100 invasive LUAD patients between January 2017 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhihua, Wu, Weibing, Pan, Xianglong, Li, Fang, Zhu, Quan, He, Zhicheng, Chen, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302275/
https://www.ncbi.nlm.nih.gov/pubmed/35289087
http://dx.doi.org/10.1002/cam4.4645
_version_ 1784751600487628800
author Li, Zhihua
Wu, Weibing
Pan, Xianglong
Li, Fang
Zhu, Quan
He, Zhicheng
Chen, Liang
author_facet Li, Zhihua
Wu, Weibing
Pan, Xianglong
Li, Fang
Zhu, Quan
He, Zhicheng
Chen, Liang
author_sort Li, Zhihua
collection PubMed
description BACKGROUND: This study aims to reveal the serum tumor marker (STM) levels in lung adenocarcinoma (LUAD) histological subtypes and evaluate their values in predicting the solid and micropapillary components (SMC). METHODS: We retrospectively analyzed 3100 invasive LUAD patients between January 2017 and December 2020. Associations between preoperative STMs (CEA, CYFRA21‐1, CA199, CA724, NSE, AFP) and LUAD subtypes were evaluated. Multivariate regression analyses were used to determine the independent predictors. Predictive models for SMC were constructed and AUC (area under the curve) was calculated. RESULTS: CEA and CYFRA21‐1 levels differed across the LUAD histological subtypes, with the SPA (solid‐predominant adenocarcinoma) having the highest level and the LPA (lepidic‐predominant adenocarcinoma) harboring the lowest level (p <0.001). Tumors with SMC also had higher CEA and CYFRA21‐1 levels than those absence of SMC. Gender, tumor size, CEA, Ki‐67, EGFR mutation (solid components only), and tumor differentiation were significantly independently associated with the containing of SMC. Patients were split into two data sets (training set: 2017–2019 and validation set: 2020). The model with gender and tumor size yielded an AUC of 0.723 (training set) and 0.704 (validation set) for the solid component. Combination of CEA, gender, and tumor size led to a significant increase in the predictive accuracy (training set: 0.771, p = 0.009; validation set: 0.747, p = 0.034). The AUC of the model for micropapillary component with only gender and tumor size was 0.699 and 0.711 in the training set and validation set, respectively. Integration of CEA with gender and tumor size significantly improved the predictive performance with an AUC of 0.746 (training set, p = 0.045) and 0.753 (validation set, p <0.001). CONCLUSION: Serum CEA and CYFRA21‐1 varied considerably according to LUAD histological subtypes. The combination of serum CEA and other factors showed prominent values in predicting the SMC.
format Online
Article
Text
id pubmed-9302275
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93022752022-07-22 Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma Li, Zhihua Wu, Weibing Pan, Xianglong Li, Fang Zhu, Quan He, Zhicheng Chen, Liang Cancer Med RESEARCH ARTICLES BACKGROUND: This study aims to reveal the serum tumor marker (STM) levels in lung adenocarcinoma (LUAD) histological subtypes and evaluate their values in predicting the solid and micropapillary components (SMC). METHODS: We retrospectively analyzed 3100 invasive LUAD patients between January 2017 and December 2020. Associations between preoperative STMs (CEA, CYFRA21‐1, CA199, CA724, NSE, AFP) and LUAD subtypes were evaluated. Multivariate regression analyses were used to determine the independent predictors. Predictive models for SMC were constructed and AUC (area under the curve) was calculated. RESULTS: CEA and CYFRA21‐1 levels differed across the LUAD histological subtypes, with the SPA (solid‐predominant adenocarcinoma) having the highest level and the LPA (lepidic‐predominant adenocarcinoma) harboring the lowest level (p <0.001). Tumors with SMC also had higher CEA and CYFRA21‐1 levels than those absence of SMC. Gender, tumor size, CEA, Ki‐67, EGFR mutation (solid components only), and tumor differentiation were significantly independently associated with the containing of SMC. Patients were split into two data sets (training set: 2017–2019 and validation set: 2020). The model with gender and tumor size yielded an AUC of 0.723 (training set) and 0.704 (validation set) for the solid component. Combination of CEA, gender, and tumor size led to a significant increase in the predictive accuracy (training set: 0.771, p = 0.009; validation set: 0.747, p = 0.034). The AUC of the model for micropapillary component with only gender and tumor size was 0.699 and 0.711 in the training set and validation set, respectively. Integration of CEA with gender and tumor size significantly improved the predictive performance with an AUC of 0.746 (training set, p = 0.045) and 0.753 (validation set, p <0.001). CONCLUSION: Serum CEA and CYFRA21‐1 varied considerably according to LUAD histological subtypes. The combination of serum CEA and other factors showed prominent values in predicting the SMC. John Wiley and Sons Inc. 2022-03-14 /pmc/articles/PMC9302275/ /pubmed/35289087 http://dx.doi.org/10.1002/cam4.4645 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Li, Zhihua
Wu, Weibing
Pan, Xianglong
Li, Fang
Zhu, Quan
He, Zhicheng
Chen, Liang
Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma
title Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma
title_full Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma
title_fullStr Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma
title_full_unstemmed Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma
title_short Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma
title_sort serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302275/
https://www.ncbi.nlm.nih.gov/pubmed/35289087
http://dx.doi.org/10.1002/cam4.4645
work_keys_str_mv AT lizhihua serumtumormarkerslevelandtheirpredictivevaluesforsolidandmicropapillarycomponentsinlungadenocarcinoma
AT wuweibing serumtumormarkerslevelandtheirpredictivevaluesforsolidandmicropapillarycomponentsinlungadenocarcinoma
AT panxianglong serumtumormarkerslevelandtheirpredictivevaluesforsolidandmicropapillarycomponentsinlungadenocarcinoma
AT lifang serumtumormarkerslevelandtheirpredictivevaluesforsolidandmicropapillarycomponentsinlungadenocarcinoma
AT zhuquan serumtumormarkerslevelandtheirpredictivevaluesforsolidandmicropapillarycomponentsinlungadenocarcinoma
AT hezhicheng serumtumormarkerslevelandtheirpredictivevaluesforsolidandmicropapillarycomponentsinlungadenocarcinoma
AT chenliang serumtumormarkerslevelandtheirpredictivevaluesforsolidandmicropapillarycomponentsinlungadenocarcinoma